Skip to main content
  • Tumor types and inpatient outcomes in patients with neurofibromatosis after brain and spinal tumor surgery

    Final Number:

    Doniel Drazin MD MA; Miriam Nuno PhD; Gregory P. Lekovic MD PhD; Chirag G. Patil MD MS

    Study Design:

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: Data on patient outcomes after surgery for neurofibromatosis have been derived from single-institution series. The objective of this study is to report inpatient complications, mortality and outcomes on a national level. This the first study to evaluate variables that may explain differences in the outcomes of NF-1 vs. NF-2 after neurological surgery.

    Methods: The National Inpatient Sample (NIS) was used to identify 3887 admissions for neurofibromatosis neurological surgery in the United States from 1998 to 2007. The effects of patient and hospital characteristics on inpatient outcomes were analyzed using logistic regression.

    Results: In-hospital mortality rate was 0.37%. Non-routine discharge rate was 23.1%. Patients with NF-1 (mean age: 23.2 years, range 1-83) were in the hospital longer (mean: 7.9 days) and had 63% more spinal tumor surgery than brain tumor surgery. Patients with NF-2 (mean age: 31.3 years, range 7-76) were in the hospital less time (mean: 6.3 days) and had more brain tumor surgery than spinal tumor surgery. Malignant tumor pathology was evident in 30.5% of brain tumors and 14% of spine tumors in NF-1 patients and in 0% and 20% in NF-2 patient tumors. Patients with NF-1 incurred over $13,000 in additional hospital charges compared to NF-2 patients. Data showed that only the NF-2 patients had inpatient mortality (N=10). Neurological complications (1.3% in NF-1;12.4% in NF-2), pulmonary complications (3.8% in NF-1;2.7% in NF-2) and postoperative hemorrhages or hematomas (1.6% in NF-1; 2.9% in NF-2) were the most common complications reported.

    Conclusions: This national study on inpatient outcomes after surgery for neurofibromatosis highlights a new finding: patients with both NF-1 and NF-2 have a significant potential for malignant spinal cord tumors. Awareness of the potential malignant pathologies for both syndromes may prompt more aggressive management of these tumors.

    Patient Care: By reporting the national data on neurofibromatosis and specifically the new awareness that malignancy can develop in patients with NF, we may be able to help the field obtain better postoperative outcomes, reduce the need for reoperations, and reduce overall costs to the patient and to society.

    Learning Objectives: 1) Understand the differences between NF-1 and NF-2 with respect to demographics of age, length of stay and outcomes. 2) Understand the common complications that arise from treating patients with NF. 3) Understand the types of tumors that are operated on for patients with NF.

    References: na

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy